Specialty Drugs Year in Review Part II: Oncology Drugs and Late-breaking FDA Actions
February 15th 2017A comprehensive review of new oncology molecular entities and previously approved oncology drugs that received expanded indications in 2016, as well as drugs approved in the final days of the year.
Read More